Stem Cell Sciences plc (SCS; AIM:STEM, ASX: STC) announces that it is to lead an EU funded, multinational novel drug screening collaboration using stem cells. The project, named “NEUROscreen”, will use Stem Cell Sciences’ proprietary neural stem (NS) cell technology and has received a contribution from the EU’s 6th Framework Programme for Research and Technical Development (FP6). The EU’s contribution to the NEUROscreen project is worth €2. [click link for full article]

More: continued here

This entry was posted on Friday, September 28th, 2007 at 5:09 am and is filed under Stem Cell Research. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.